113981-44-5
113981-44-5 結(jié)構(gòu)式
基本信息
頭孢唑蘭鹽酸鹽
1-[[(6R,7R)-7-[(Z)-2-(5-氨基-1,2,4-噻二唑-3-基)-2-甲氧亞氨基乙酰胺基]-2-羧基-8-氧代-5-硫雜-1-氮雜雙環(huán)[4.2.0]辛-2-烯-3-基]甲基]咪唑并[1,2-B]噠嗪內(nèi)鹽鹽酸鹽
1-[[(6R,7R)-7-[(Z)-2-(5-氨基-1,2,4-噻二唑-3-基)-2-甲氧亞氨基乙酰胺基]-2-羧基-8-氧代-5-硫雜-1-氮雜雙環(huán)[4.2.0]辛-2-烯-3-基]甲基]咪唑并[1,2-b]噠嗪鎓內(nèi)鹽鹽酸鹽
D02233
Firstcin (tn)
Cefozopran hydrochlo
SCE-2787 hydrochloride
Cefozopran hydrochloride
Cefozopran hydrochloride (jp15)
Cefozopran hydrochloride USP/EP/BP
(6R,7R)-7-[[(2E)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[2,3-f]pyridazin-4-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid chloride
物理化學性質(zhì)
應用領域
常見問題列表
Cefozopran (SCE-2787) is a fourth-generation cephalosporin that has good activity against gram-positive organisms including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci; and against gram-negative organisms including hemophilus influenza. Moreover, cefozopran has comparatively good activity against enterococci and P. aeruginosa , which are refractory to other cephalosporins.
Cefozopran (SCE-2787) (5-80 mg/kg; s.c.; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In the model of chronic respiratory tract infection caused by K. pneumoniae 27, Cefozopran (20-80 mg/kg; s.c.; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime.